MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 414.4% in July

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 1,200,000 shares, agrowthof414.4% from the June 30th total of 233,300 shares. Based on an average daily volume of 1,490,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately9.3% of the company’s shares are sold short. Approximately9.3% of the company’s shares are sold short. Based on an average daily volume of 1,490,000 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRA. Renaissance Technologies LLC purchased a new position in shares of MIRA Pharmaceuticals during the fourth quarter worth approximately $52,000. Northern Trust Corp increased its position in shares of MIRA Pharmaceuticals by 50.9% during the fourth quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after acquiring an additional 10,238 shares during the period. Citadel Advisors LLC purchased a new position in shares of MIRA Pharmaceuticals during the fourth quarter worth approximately $112,000. Two Sigma Investments LP purchased a new position in shares of MIRA Pharmaceuticals during the fourth quarter worth approximately $28,000. Finally, Suncoast Equity Management increased its position in shares of MIRA Pharmaceuticals by 356.1% during the first quarter. Suncoast Equity Management now owns 103,289 shares of the company’s stock worth $101,000 after acquiring an additional 80,645 shares during the period. 35.16% of the stock is owned by hedge funds and other institutional investors.

MIRA Pharmaceuticals Price Performance

MIRA Pharmaceuticals stock opened at $1.54 on Friday. MIRA Pharmaceuticals has a 1-year low of $0.73 and a 1-year high of $2.79. The firm has a market capitalization of $26.06 million, a P/E ratio of -3.02 and a beta of 1.76. The company’s 50-day moving average is $1.40 and its 200 day moving average is $1.20.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its earnings results on Wednesday, May 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Research analysts anticipate that MIRA Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.